Exendin-4, liraglutide and other GLP-1 receptor agonists reduced the amyloid plaque formation in patients with T2DM, MS and AD, the same refers to mice with insulin resistance and T1DM. Here, GLP1R is linked to type 2 diabetes mellitus.